Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234702 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease
A Phase 2 study of Kidney Diseases, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 10
- Study locations
NCT00234702: Completed Phase 2 study of Kidney Diseases, sponsored by Shire.
NCT00234702 is a Phase 2 study of Kidney Diseases that has completed, run by Shire. The registered enrollment target is 84 participants, below the 1,783-participant average among 38 other Kidney Diseases trials with a reported enrollment target (95% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234702, a Phase 2 study of Kidney Diseases, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 10
- Study locations
Study Summary
Chronic kidney disease (CKD) can result in a loss of ability to filter and excrete phosphate. The body's attempt to adjust to an increased level of phosphate in the blood can result in elevated levels of hormones and minerals resulting in serious clinical consequences. This study is being conducted to evaluate the safety and efficacy of lanthanum carbonate in lowering high levels of phosphorus in the blood in subjects with CKD Stages 3 and 4 compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lanthanum carbonate
Study Locations (10)
California
- VA Greater Los Angeles Health Care System - Los Angeles
- Barnett Research & Communications Medical Corporation - Torrance
Colorado
- Western Nephrology & Metabolic Bone Disease, PC - Thornton
Florida
- Outcomes Research International, Inc. - Hudson
Minnesota
- Twin Cities Clinical Research - Brooklyn Center
Missouri
- St. Louis University/Nephrology - St Louis
North Carolina
- University of North Carolina - Chapel Hill
Oregon
- Northwest Renal Clinic - Portland
Tennessee
- Nephrology Associates - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2006-01-11 |
| Est. Completion | 2007-06-01 |
| Phase | Phase 2 |
What the finished NCT00234702 record still lists
NCT00234702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 1,783-participant average among 38 other Kidney Diseases trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00234702 lists 10 locations in 9 states (California, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT00234702 about?
NCT00234702 is a clinical study titled "Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease". Chronic kidney disease (CKD) can result in a loss of ability to filter and excrete phosphate. The body's attempt to adjust to an increased level of phosphate in the blood can result in elevated levels of hormones and minerals resulting in serious clinical consequences. This study is being conducted ...
What is the current status of trial NCT00234702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2006-01-11. Estimated completion is 2007-06-01.
What conditions does trial NCT00234702 study?
This clinical trial studies the following conditions: Kidney Diseases.
What interventions are being tested in trial NCT00234702?
The interventions under investigation include: Placebo (DRUG), Lanthanum carbonate (DRUG).
Who is sponsoring clinical trial NCT00234702?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00234702 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00234702's enrollment target sits among peer trials
84 24th of 38 higher than 15 of 38 other Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
COMPLETED · Phase 2
-
A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures
COMPLETED · Phase 2
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
-
Supporting VETerans With Kidney Disease Through Food As Medicine
RECRUITING · NA
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI